STAT· @statnews · X·· 7 天前AI 评分42
AI 导读
生物技术公司 PepGen 表示,在一项关键指标上,其试验性药物在治疗一种影响超过 10 万人的肌肉疾病的竞赛中,显示出迄今为止最有希望的早期数据。https://www.statnews.com/2026/11/10/muscular-dystrophy-dm1-pepgen-pgn-edodm1-early-results/
正文
The biotech PepGen said that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a muscle disorder that affects over 100,000 people. https://www.statnews.com/2026/11/10/muscular-dystrophy-dm1-pepgen-pgn-edodm1-early-results/
来源:STAT · x.com